Skip to main content
Erschienen in: Rheumatology International 10/2013

01.10.2013 | Short Communication

Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients

verfasst von: Benigno Casanueva, Baltasar Rodero, Covadonga Quintial, Javier Llorca, Miguel A. González-Gay

Erschienen in: Rheumatology International | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to evaluate the short-term efficacy of topical capsaicin treatment in patients severely affected by fibromyalgia. One hundred and thirty fibromyalgia patients were randomly divided into two groups. The control group, 56 women and 4 men who continued their medical treatment, and the capsaicin group, 70 women who apart from continuing their medical treatment, also underwent topical capsaicin 0.075 % 3 times daily for 6 weeks. At the beginning of the program, there were no significant differences between the two groups in any of the analyzed parameters. At the end of the treatment, there were significant improvements in the capsaicin group in the myalgic score (5.21 vs 3.8, p = 0.02) and global subjective improvement (22.8 vs 5 %, p = 0.001). Six weeks after the end of the treatment, the experimental group showed significant differences in Visual Analogue Scale of depression (5.63 vs 7.35, p = 0.02), Fibromyalgia Impact Questionnaire (67.89 vs 77.7, p = 0.02), role limitations due to emotional problems (36.17 vs 17.2, p = 0.05), Fatigue Severity Scale (6.2 vs 6.6, p = 0.04), myalgic score (3.94 vs 2.66, p = 0.02) and pressure pain threshold (79.25 vs 56.71, p = 0.004). In conclusion, patients severely affected by fibromyalgia can obtain short-term improvements following topical capsaicin 0.075 % treatment three times daily for 6 weeks.
Literatur
1.
Zurück zum Zitat Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172PubMedCrossRef Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172PubMedCrossRef
2.
Zurück zum Zitat Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305PubMedCrossRef Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305PubMedCrossRef
3.
Zurück zum Zitat Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63PubMedCrossRef Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63PubMedCrossRef
4.
Zurück zum Zitat Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601PubMedCrossRef Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601PubMedCrossRef
5.
Zurück zum Zitat Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145PubMedCrossRef Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145PubMedCrossRef
6.
Zurück zum Zitat Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199PubMedCrossRef Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199PubMedCrossRef
7.
Zurück zum Zitat Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991PubMedCrossRef Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991PubMedCrossRef
8.
Zurück zum Zitat Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274PubMedCrossRef Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274PubMedCrossRef
9.
Zurück zum Zitat Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151 Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151
10.
Zurück zum Zitat Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137PubMedCrossRef Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137PubMedCrossRef
11.
Zurück zum Zitat Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124PubMedCrossRef Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124PubMedCrossRef
12.
Zurück zum Zitat Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94 Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94
13.
Zurück zum Zitat Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897CrossRef Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897CrossRef
14.
Zurück zum Zitat Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRef Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRef
15.
Zurück zum Zitat García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492CrossRef García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492CrossRef
16.
Zurück zum Zitat Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560PubMed Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560PubMed
17.
Zurück zum Zitat Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20PubMedCrossRef Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20PubMedCrossRef
18.
Zurück zum Zitat Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16PubMedCrossRef Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16PubMedCrossRef
19.
Zurück zum Zitat Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454CrossRef Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454CrossRef
20.
Zurück zum Zitat Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166PubMedCrossRef Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166PubMedCrossRef
21.
Zurück zum Zitat Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207PubMedCrossRef Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207PubMedCrossRef
22.
Zurück zum Zitat McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47CrossRef McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47CrossRef
23.
Zurück zum Zitat Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, Junio Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, Junio
24.
Zurück zum Zitat Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73PubMedCrossRef Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73PubMedCrossRef
25.
Zurück zum Zitat Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749CrossRef Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749CrossRef
Metadaten
Titel
Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients
verfasst von
Benigno Casanueva
Baltasar Rodero
Covadonga Quintial
Javier Llorca
Miguel A. González-Gay
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 10/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2490-5

Weitere Artikel der Ausgabe 10/2013

Rheumatology International 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.